Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders
Advanced Science · 2026-09 · 13 (50)
DOI: 10.1002/advs.77142 ↗At a glance
Übersichtsarbeit in Advanced Science, published online on 2026-08-11. Written by Kaige Chen and 1 co-authors. Institution: Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA. Major MEDLINE topics: Protein Engineering, Antibodies. Cited 1 times so far (Crossref); 97 references. The full text is freely available (open access, CC BY 4.0). Funded by: METAVIVOR Foundation Early Career Research Grant Award to Q.H., American Cancer Society Research Scholar, NIBIB NIH HHS, NCI NIH HHS.
Abstract (original language)
Targeted chimeras have reshaped therapeutic design by converting target recognition into active degradation. As one of the most clinically established therapeutic modalities, antibodies provide high affinity and specificity to the protein of interest. Antibody‐associated targeted chimeras (AbTACs) are emerging as an important class of biologic degraders for targeted protein elimination, particularly of extracellular and membrane‐associated proteins. AbTACs offer a strategy to extend its recognition capacity beyond target binding by coupling defined degradation pathway. In these systems, antibody‐derived binders serve as programmable recognition modules, while conjugated ligands, encoded domains, recruited receptors, or nanoparticle scaffolds determine the target's intracellular fate. This review discusses the conceptual evolution of AbTACs and classifies current platforms according to scaffold architecture and engineering strategies, which link target binding to intracellular routing and subsequent clearance. Furthermore, it highlights the design principles and translational barriers that will guide the development of next‐generation antibody‐associated degraders.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Wisconsin Center for NanoBioSystems, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Lachman Institute for Pharmaceutical Development, University of Wisconsin, Madison, Wisconsin, USA.
ORCID profiles: Quanyin Hu
Funding
- METAVIVOR Foundation Early Career Research Grant Award to Q.H., American Cancer Society Research Scholar
- NIBIB NIH HHS
- NCI NIH HHS
- start-up package from the University of Wisconsin-Madison
- Lachman Institute Research Funds, and Joseph R. and Bonna A. Robinson Chair fund
- University of Wisconsin Carbone Cancer Center Research Collaborative and the Pancreas Cancer Task Force
- National Institute of Biomedical Imaging and Bioengineering
- National Cancer Institute
Cite
APA
Chen, K., & Hu, Q. (2026). Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders. Advanced Science, 13(50). https://doi.org/10.1002/advs.77142
Vancouver
Chen K, Hu Q. Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders. Advanced Science. 2026;13(50). doi:10.1002/advs.77142
BibTeX
@article{Chen2026,
author = {Chen, Kaige and Hu, Quanyin},
title = {Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {50},
doi = {10.1002/advs.77142}
}
EUVIMED